Adding Liraglutide to Metformin May Reduce Cardiovascular Risk

Low Bilirubin Predicts Coronary Artery Disease Risk in Metabolic Syndrome
Low Bilirubin Predicts Coronary Artery Disease Risk in Metabolic Syndrome
Liraglutide plus metformin can reduce cardiovascular risk in patients with type 2 diabetes.

Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated.

Objective: We evaluated the impact of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes (T2DM).

Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings appeared to be independent of the known effects of liraglutide on glucose metabolism.

READ FULL ARTICLE Curated publisher From press.endocrine.org